Elixiron Immunotherapeutics attracts $27m

Elixiron Immunotherapeutics Inc, a developer of therapeutics for cancer, neurological diseases and inflammatory disorders, has closed its Series A-1 funding round at $27 million.

Elixiron Immunotherapeutics Inc, a developer of therapeutics for cancer, neurological diseases and inflammatory disorders, has closed its Series A-1 funding round at $27 million. Pangu Capital and Taiwania Capital led the round.

Source: Press Release